Projects approved for funding in 2021
| Code | Title | Organisation | Lead PI | Funding Amount | Abstract | Final Summary |
| TCS/21/02 | Development of a novel anti-cancer Natural Killer cell-based immunotherapy | University of Glasgow | Professor Gerard Graham | £299,999 | TCS/21/02 Abstract | TCS/21/02 Final Summary |
| TCS/21/03 | Early detection of Alzheimer’s disease with glucoCEST MRI: a proof of concept study | University of Aberdeen | Dr Gordon Waiter | £260,978 | TCS/21/03 Abstract | TCS/21/03 Final Summary |
| TCS/21/04 | A single-centre, randomised, open label, blinded end-point, safety and efficacy trial of conventional versus higher dose acetylcysteine in patients with paracetamol overdose. (The High SNAP Trial). | University of Edinburgh | Professor James Dear | £295,509 | TCS/21/04 Abstract | Project Active |
| TCS/21/05 | Developing representative models of the blood-tumour barrier to enhance drug development for glioblastoma. | University of Glasgow | Professor Anthony Chalmers | £296,864 | TCS/21/05 Abstract | Project Active |
| TCS/21/09 | Proof-of-concept for using a novel formulation of metformin (Metformin Delayed Release) to optimise treatment of gestational diabetes | University of Edinburgh | Professor Rebecca Reynolds | £299,259 | TCS/21/09 Abstract | TCS/21/09 Final Summary |
| TCS/21/11 | PRevention and Early detection of Breast cancer in high-RISK premenopausal population through mammary lipid composition using novel imaging | University of Aberdeen | Dr Jiabao He | £296,114 | TCS/21/11 Abstract | TCS/21/11 Final Summary |
| TCS/21/25 | Dissecting the transcriptomic and phenotypic reprogramming of myeloid cells that mediate chemoresistance in cholangiocarcinoma | University of Glasgow | Dr Chiara Braconi | £299,997 | TCS/21/25 Abstract | TCS/21/25 Final Summary |
| TCS/21/30 | A window in the brain 2: Novel quantitative seizure detection tool for paediatric critical care. A multi-centre feasibility study | University of Edinburgh | Dr Tsz-Yan Milly Lo | £298,740 | TCS/21/30 Abstract | TCS/21/30 Final Summary |
| TCS/21/31 | Targeting investigation and treatment in patients with type 2 myocardial infarction (TARGET – Type 2): A pilot randomised controlled trial | University of Edinburgh | Dr Andrew Chapman | £258,738 | TCS/21/31 Abstract | TCS/21/31 Final Summary |
| TCS/21/39 | PET/MRI (Positron Emission Tomography/Magnetic Resonance Imaging) to Improve Staging and Personalise Treatment for Prostate Cancer: PRISTINE Study | University of Edinburgh | Dr Rishi Ramesh / Dr David Noble | £276,554 | TCS/21/39 Abstract | Project Active |
| TCS/21/43 | First in Human Clinical Trial of SARS-CoV-2 Allogeneic Virus Specific T cells | Scottish National Blood Transfusion Service | Professor Marc Turner | £280,403 | TCS/21/43 Abstract | TCS/21/24 Final Summary |